Journal of Cancer Research and Therapeutics

LETTER TO THE EDITOR
Year
: 2010  |  Volume : 6  |  Issue : 4  |  Page : 588-

Irinotecan as a maintenance therapy for hepatoblastoma: A comment


V Wiwanitkit 
 Wiwanitkit House, Bang Khae, Bangkok, Thailand

Correspondence Address:
V Wiwanitkit
Wiwanitkit House, Bang Khae, Bangkok 10160
Thailand




How to cite this article:
Wiwanitkit V. Irinotecan as a maintenance therapy for hepatoblastoma: A comment.J Can Res Ther 2010;6:588-588


How to cite this URL:
Wiwanitkit V. Irinotecan as a maintenance therapy for hepatoblastoma: A comment. J Can Res Ther [serial online] 2010 [cited 2022 May 27 ];6:588-588
Available from: https://www.cancerjournal.net/text.asp?2010/6/4/588/77092


Full Text

Sir,

Several novel therapeutic approaches for the treatment of children with hepatoblastoma are currently available. Irinotecan is a new drug proposed for its effectiveness in high-risk patients with hepatoblastoma. [1] Qayed et al. found that irinotecan can be used as an effective maintenance therapy for hepatoblastoma. [2] However, hepatoblastoma is rare and clinical trials on irinotecan have usually included only a few subjects. Hence, it remains uncertain whether irinotecan is the optimal treatment for hepatoblastoma. Side effects of irinotecan should also be of concern. An important serious side effect of irinotecan is chemotherapy-induced diarrhea that can be a significant problem for patients. [3] For the studies with few subjects, it might be difficult to assess the magnitude of this side effect of irinotecan. Another important side effect is the genotoxicity. It should be noted that increased vitamin A, C and E of cells exposed to irinotecan is related to increased degree of genotoxicity. [4] Hence, vitamin status should be addressed in using irinotecan for the treatment of hepatoblastoma.

References

1Katzenstein HM, Rigsby C, Shaw PH, Mitchell TL, Haut PR, Kletzel M. Novel therapeutic approaches in the treatment of children with hepatoblastoma. J Pediatr Hematol Oncol 2002;24:751-5.
2Qayed M, Powell C, Morgan ER, Haugen M, Katzenstein HM. Irinotecan as maintenance therapy in high-risk hepatoblastoma. Pediatr Blood Cancer. 2010.
3Richardson G, Dobish R. Chemotherapy induced diarrhea. J Oncol Pharm Pract 2007;13:181-98.
4Kontek R, Drozda R, Sliwinski M, Grzegorczyk K. Genotoxicity of irinotecan and its modulation by vitamins A, C and E in human lymphocytes from healthy individuals and cancer patients. Toxicol in Vitrol 2009.